The present invention provides a new procedure for the preparation of monolithic systems from ceramic or carbonaceous materials using the […]
Author: Viromii
Phage therapy, the solution for multiresistant bacteria?
Recently, at Viromii, we have been working on a really interesting project regarding phage therapy, a promising area that can help […]
Innovative strategies for extending drugs’ market exclusivity.
In the previous post, we explored the different preventive strategies pharma companies use to maintain their market exclusivity. At Viromii we feel this […]
SME Phase 1, one last call and a long-lasting impact in almost 4000 Start-ups.
For some time at Viromii we have been developing a tool that facilitates technology transfer activities by helping experts identify […]
Preventive strategies for extending drugs’ market exclusivity in US and EU.
In the previous post we could see the greatly negative impact that losing market exclusivity has over the financials of pharmaceutical companies, […]
When pharma companies lose control and exclusivity over a blockbuster.
Lately, at Viromii, we have been working with some really interesting projects in the pharma industry, this has made us […]
Guidelines for creating a TTO, what do you have to bear in mind before taking the step?
In the previous post, we explained the impact of the teacher’s exemption over university’s technology transfer performance. However, in this […]
Professor’s privilege, does it really impact technology transfer?
Universities are the cradle of knowledge, new technologies and innovation. These new technologies and innovations can be the base for […]
Which are the most important performance parameters in ventures and startups?
We, at Viromii. have asked this question to many actors within the european startup ecosystem, and found interesting insights that […]